For the supportive treatment of the second type of diabetes mellitus , in which the production of insulin molecules occurs, glyclazide-based products are used. This substance is a sulfonylurea derivative belonging to the second generation.
general characteristics
The medicine "Glidiab MV 30" is considered the Russian analogue of the French drug "Diabeton MV". It is produced by the Akrikhin Chemical and Pharmaceutical Plant in the Moscow Region.
The medication refers to oral hypoglycemic agents in tablet form having a modified release. The color of their structure is white or cream, may be marble blotches. Tablets resemble flat chamfers.
Consumer packaging is a pack. It may contain 30 or 60 tablets, packaged in blister plates.
Structure
Unlike the medicine “Diabeton MV” with a dose of 0.060 g of gliclazide, the drug “Glidiab MV” has an amount of identical active ingredient two times lower, which is 0.030 g.
Inactive tablet components include hydroxypropyl methylcellulose, aerosilic molecules, magnesium stearate, microcrystalline cellulose.
There is also the drug "Glidiab" with the usual release of the active substance. The dosage in one tablet is 0.08 g of gliclazide.
How does it work
The instructions for use attached to the Glidiab MV medication describe the effect of glyclazide, which stimulates insulin secretion in β-cells located in the pancreas.
Under the influence of tablets, the insulin secretory activity of glucose molecules increases, and peripheral tissues become more sensitive to the insulin hormone.
Muscle glycogen synthetase, being an intracellular enzyme, is more effective. There is a decrease in the interval from the start of eating to the release of the hormone. Insulin secretion is restored at an early peak, which distinguishes gliclazide from other sulfonylurea precursors, the action of which occurs in the second stage. The postprandial glucose level decreases.
There is an improvement in microcirculation by combining and sticking platelets, normalizing the permeability of the vascular wall, reducing the development of microthrombotic and atherosclerosis processes, restoring the reactions of the natural dissolution of blood clots. The possibility of the reaction of receptor formations in vessels to adrenaline molecules decreases.
The drug is able to slow down the diabetic nature of retinopathy at the non-proliferative stage. Long-term treatment with this drug in conditions of diabetic damage to the components of the renal parts responsible for filtration can significantly reduce the excretion of proteins in the urine.
The medication does not increase the body mass, but rather reduces it due to the effect on the early stage of insulin secretion. It does not provoke increased insulinemia.
What is it used for?
Doctors recommend using the drug with high blood sugar of the second degree. Treatment is carried out with insufficient effect of the diet and moderate physical activity.
For the Glidiab MV medication, the indications are associated with the prevention of deterioration in diabetic disorders, characterized by nephropathy, retinopathy, myocardial infarction and stroke.
How to use
The dosage of the drug is selected for each patient separately, taking into account the manifestations of the disease, glucose concentration with an empty stomach and 120 minutes after eating.
For the medicine “Glidiab MV”, the instructions for use prescribe a daily initial dose of 0.03 g, which is equivalent to one tablet. This concentration is indicated for elderly patients after 65 years of age. The medication is used orally one tablet in the morning when breakfast.
If necessary, the dosage is increased every two weeks. A maximum of one day is allowed to take about 0.120 g, which corresponds to 4 tablets.
The medicine "Glidiab MV" is used instead of the drug of the same name with the usual release, consuming 1-4 tablets per day.
It is combined with a hypoglycemic agent based on biguanide, an alpha-glucosidase inhibitor of insulin molecules.
In case of impaired renal work of a weak or moderate nature, when the rate of creatinine excretion is not more than 0.080 liters per minute, the dosage is not reduced.
When not to take
Glidiab MV tablets are not recommended for use in the first form of diabetes mellitus, with an increase in ketones in the urine, with gastric paresis, with hyperosmolar, diabetic coma and precoma, with major surgeries and burn injuries, traumatic processes when insulin is needed treatment.
Contraindications are severe violations of hepatic or renal functioning, bowel obstruction, changes in food absorption, the development of a hypoglycemic state.
You can not use the drug for fever, leukopenia, pregnancy, breastfeeding and excessive intolerance to the ingredients of the drug.
Caution is required when administering the medication, special supervision and dosage selection for patients with alcohol dependence and disorders in the thyroid gland.
Treatment features
For the medicine "Glidiab MV", the instructions for use indicate the need to combine it with a low-calorie diet, including low carbohydrate content. Regular monitoring of the concentration of glucose in the bloodstream from the morning before and after eating is required.
If there were surgical interventions or decompensation of the diabetic condition, the introduction of insulin agents is possible.
There are warnings about the occurrence of a hypoglycemic process with the use of ethyl alcohol, a non-steroidal anti-inflammatory substance and lack of nutrition. Drinking alcohol can cause a disulfiram-like syndrome, while the head and stomach hurt, and nausea and vomiting are possible.
The dosage of the drug should be adjusted during physical or emotional stress and with untimely food intake.
Especially sensitive to the effect of the drug are the elderly, patients with unbalanced or poor nutrition, weakened patients who suffer from insufficiency of the adrenal-pituitary system.
At the initial stages of the use of the drug when choosing a dosage, if there is a predisposition to a hypoglycemic crisis, you do not need to perform actions that require increased attention and a quick psychomotor reaction.
Adverse reactions
For Glidiab MV, the instruction includes information on abnormalities in the endocrine organs during a malfunction in the regimen of tablet use and in case of improper nutrition. Typically, a decrease in the level of glucose in the bloodstream causes the occurrence of pain in the head, tired, hungry, helpless, anxious state of health, instant weakness, aggression, weak concentration, and depressive state. Also, there are changes in visual perception, tremors, sensory and convulsive disorder, dizziness, hypersomnia, shallow breathing, decreased heart rate.
The digestive organs malfunction in the form of malabsorption, nausea, diarrhea, anorexic lack of appetite, impaired functioning of liver cells, cholestatic jaundice, and an increase in the effectiveness of transaminase enzymes.
Undesirable processes in the hematopoietic system are associated with a decrease in hemoglobin, platelet and white blood cell counts.
The drug can cause allergic manifestations in the form of itching, urticaria, maculopapular rash.
Excess introduction
The instructions for use attached to the Glidiab MV product warns against overdose, which is expressed by a decrease in glucose concentration in blood plasma. With a strong excess of the drug, the development of a hypoglycemic coma is possible.
To eliminate it, a person is allowed to eat some well-absorbed hydrocarbons, for example, a piece of sugar. When a person is unconscious, he is injected with a 40% dextrose or glucose solution into a vein, and glucagon is injected into the muscle in an amount of 1 mg. If the patient wakes up, then he is forced to eat well-absorbed hydrocarbons to avoid a repeat of the hypoglycemic attack.
Combination with medicines
The hypoglycemic activity of the drug “Glidiab MV 30 mg” can be enhanced by the parallel administration of a moderator enzyme angiotensin converting and monoamine oxidase type, beta-adrenergic and H2-histamine-dependent receptor blocker based on cimetidine, antifungal miconazole and fluconazole drugs, non-steroidal anti-inflammatory substances phenylbutazone, indomethacin, diclofenac.
The effect of the tablets is enhanced with clofibrates and bezafibrates, anti-TB drugs from the group of ethionamide, salicylates, indirect anticoagulant compounds of the coumarin structure, anabolic steroids, cyclophosphamides, chloramphenicol, sulfonamides with prolonged effect.
The drug more effectively reduces blood sugar in the blood plasma, if you use tubular blockers, ethyl alcohol, acarbose, biguanide, insulin.
Reducing the hypoglycemic effect of tablets is caused by barbiturates, drugs based on epinephrine, clonidine, terbutaline, rhytodrin, salbutamol, phenytoin, inhibitors of the carbonic anhydrase enzyme such as acetazolamide, thiazide diuretics, hormones of the thyroid gland, lithium-containing medications, and lithium-containing medications.
Molecules of ethyl alcohol are able to act on gliclazide with the occurrence of a disulfiram-like process.
The active component of the tablets causes untimely depolarization and contraction of the ventricles of the myocardial muscle when combined with cardiac glycosides.
Beta-blockers, clonidine, reserpine, guanethidine drugs mask clinical hypoglycemia.
Patient opinions
Not only the instructions for use attached to the Glidiab MV medication are important. Reviews talk about what patients think about the effectiveness of the drug. This tool helps many patients reduce the glucose concentration to normal values, and in combination with a diet changes the patient’s way of life.
People note that the positive feature of the tablets is their convenient use in the morning. During the day, you can not remember the need for treatment.
On the medicine "Glidiab MV" reviews can be heard and negative in nature, associated with the ineffectiveness of this tool. This usually happens when the dosage is incorrect, when a small amount of the drug is prescribed.